Insider Buying: Attovia Therapeutics (NASDAQ:ATTO) Director Purchases $1,785,000.00 in Stock

Posted by Shane Hupp on Aug 14th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) Director Colin Walsh purchased 85,000 shares of the stock in a transaction on Wednesday, August 5th. The shares were purchased at an average price of $21.00 per share, with a total value of $1,785,000.00. Following the acquisition, the director directly owned 85,000 shares in the company, valued at $1,785,000. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Colin Walsh also recently made the following trade(s):

On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96.
On Thursday, August 6th, Colin Walsh acquired 500,000 shares of Attovia Therapeutics stock. The stock was purchased at an average price of $17.00 per share, for a total transaction of $8,500,000.00.

Attovia Therapeutics Trading Up 6.2%

Attovia Therapeutics stock opened at $19.18 on Friday. Attovia Therapeutics, Inc. has a 12-month low of $16.15 and a 12-month high of $22.79.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. increased its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

Attovia Therapeutics Company Profile

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.